NASDAQ: VCNXVaccinex Inc Stock
$5.01+0.05 (+1.01%)
Updated Apr 24, 2024
VCNX Price
$5.01
Fair Value Price
N/A
Market Cap
$6.16M
52 Week Low
$4.43
52 Week High
$100.80
P/E
-0.11x
P/B
-2.67x
P/S
7.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$570.00k
Earnings
-$20.25M
Gross Margin
100%
Operating Margin
-3,552.63%
Profit Margin
-3,552.8%
Debt to Equity
-2.57
Operating Cash Flow
-$17M
Beta
0.41
Next Earnings
May 13, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VCNX Overview
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VCNX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VCNX is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VCNX is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
VCNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more VCNX due diligence checks available for Premium users.
Be the first to know about important VCNX news, forecast changes, insider trades & much more!
VCNX News
Valuation
VCNX fair value
Fair Value of VCNX stock based on Discounted Cash Flow (DCF)
Price
$5.01
Fair Value
-$0.03
Undervalued by
15,493.81%
VCNX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VCNX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.11x
Industry
15.69x
Market
41.27x
VCNX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-2.67x
Industry
5.86x
VCNX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
VCNX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VCNX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$3.6M
Liabilities
$5.9M
Debt to equity
-2.57
VCNX's short-term liabilities ($5.92M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VCNX's short-term assets ($3.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VCNX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VCNX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.6M
Investing
$0.0
Financing
$5.0M
VCNX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VCNX vs Biotech Stocks
Vaccinex Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.